Drugs Made In America Acquisition Corp
DMAA
37 hedge funds and large institutions have $223M invested in Drugs Made In America Acquisition Corp in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
16% more funds holding
Funds holding: 32 → 37 (+5)
5% more capital invested
Capital invested by funds: $212M → $223M (+$11.1M)
2.79% more ownership
Funds ownership: 62.13% → 64.91% (+2.8%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$5.13M |
| 2 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$4.12M |
| 3 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$3.26M |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
+$2.56M |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$2.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$3.57M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.56M |
| 3 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$2.02M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.52M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.02M |
DMAA Hedge Fund Activity: Q3 2025 in Review
37 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp (DMAA) for Q3 2025, worth a combined $223M — up 5.2% from $212M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DMAA positions and 5 closed out — a net gain of 5 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $5.13M. The largest seller was Mangrove Partners, exiting entirely with an estimated $3.57M sold.
- 37 institutional investors held Drugs Made In America Acquisition Corp (DMAA) as of Q3 2025, up from 32 in Q2 2025.
- Funds reported $223M of Drugs Made In America Acquisition Corp stock for Q3 2025, up 5.2% quarter-over-quarter.
- 10 funds opened new Drugs Made In America Acquisition Corp positions in Q3 2025 and 5 closed out, a net change of +5 holders.
- The largest Drugs Made In America Acquisition Corp buyer in Q3 2025 was J. Goldman & Co, an estimated $5.13M added.
- The largest Drugs Made In America Acquisition Corp seller in Q3 2025 was Mangrove Partners, an estimated $3.57M sold.
Based on aggregated 13F filings for Q3 2025.